source
- Moonwalk Biosciences raises $70M and pivots to RNAi obesity drug developmentMoonwalk Biosciences, a California biotech founded in 2024, announced a new $70 million venture funding round. The capital will support development of its first obesity drug, which uses RNA interf…
- Inhibrx reports promising responses to OX40 immunotherapy in HPV-positive head and neck cancerInhibrx announced that its experimental immunotherapy targeting the protein OX40 produced measurable responses in patients with head and neck cancer, with the clearest activity observed in a small…